International Biotechnology Trust: New
research
11/04/2018
A well-resourced biotechnology fund that has
produced double digit annualised returns under the current manager,
offering a yield of 4%...
Click here to read the full report
Highlights:
· Targets a yield
of 4% and has seen its dividend increase 17.4% since it was
introduced at the start of 2017, drawing income from
capital
· Moved from a
double digit discount at the start of 2017 to a premium earlier
this year, but lost some ground during the market volatility in
February and now trades at a discount of 5%
· The managers believe biotech
could prosper under a new 'business friendly' FDA chief in the
United States, where 90% of the portfolio is held, with biotech
stocks in the US trading at a rare discount to the broader
market
· A highly-experienced management team with a focus on avoiding 'key risk events'. The
trust has delivered annualised NAV total returns of 17.35% per
annum since lead manager Carl Harald Janson took the
reins
Visit http://www.trustintelligence.co.uk/investor for more
high quality independent investment trust research.
Not for distribution, directly or indirectly, in or into the
United States or any jurisdiction in which such distribution would
be unlawful.
Important information - non-independent research
International Biotechnology
Trust a client of Kepler Trust Intelligence. This material
should be considered a marketing communication, and is not
independent research.
This report has been approved under section 21 of the Financial
Services and Markets Act 2000 by Kepler Partners LLP for
communication to retail clients and private persons as defined by
the Financial Services Authority. This is a marketing document, and
should be considered non-independent research as defined in COBS
12.3.2R. It has not been prepared in accordance with legal
requirements designed to promote the independence of investment
research. Kepler Partners LLP (including its partners, employees
and representatives) or a connected person may have positions in or
options on the securities detailed in this report, and may buy,
sell or offer to purchase or sell such securities from time to
time, subject to restrictions imposed by internal rules. This is
not an official confirmation of terms and is not a recommendation,
offer or solicitation to buy or sell. Any prices or quotations
contained herein are indicative only. The information in this
report is believed to be correct, but its accuracy or completeness
cannot be guaranteed. No representation or warranty, express or
implied, is given by any person as to the accuracy or completeness
of the information and no responsibility or liability is accepted
for the accuracy or sufficiency of any of the information, for any
errors, omissions or misstatements, negligent or otherwise. Please
remember that past performance is not necessarily a guide to the
future. The value of investments can fall as well as rise and you
may get back less than you invested when you decide to sell your
investments. Independent financial advice should be taken before
entering into any financial transaction. Kepler Partners LLP is a
limited liability partnership registered in England and Wales at
9/10 Savile Row, London W1S 3PF with registered number OC334771.
Kepler Partners LLP is authorised and regulated by the Financial
Conduct Authority.
Click here to read our terms and conditions.
About this service
Kepler Trust Intelligence for private investors is not just
another news and research website. Our aim is to create a library
of high quality investment strategy research, fund analysis and
useful guides for private investors, all written in-house by
experienced analysts on the investment companies team at Kepler
Partners.
We are focused entirely on investment trusts, however we believe
that it helps to understand them better if they are placed on a
level playing field with OEICs, so you will see comparisons between
the two in these pages often.
Our content falls into three categories;
· Investment strategy articles are
designed to highlight opportunities and developments which are of
interest to investment trust investors, positive or negative.
· Fund research focuses on individual
trusts, examining them in detail to create a snapshot picture which
you can use to decide whether or not you want to invest in
them.
· Educational output is split into simple
guides, designed to help beginners understand how investment trusts
work, and more complex guides to sectors, regions and strategies
which may be of interest to investors.
We do not produce massive amounts of research. Our focus is on
quality, not quantity, so we are unlikely to publish more than four
or five articles in a given week. For this reason we recommend that
you join our mailing list, and we'll send you an email once a week
alerting you to what's new on the site. We won't sell your details,
and we won't spam you with useless updates.
How are we funded?
Our revenues are based on advertising from the asset management
groups, which run investment trusts, and want exposure to an
audience which is engaged with authentic, useful content.
Our advertisers can insert links to their own material - videos
for example - into the content, and they can pay for a page where
they can talk about their own products in the edition.
Investment trusts can also pay for us to write a piece of
research about them specifically, and where we do this will be
clearly marked as 'non-independent research'.
Where we do produce research on a 'paid-for' basis we strive to
ensure that a clear, useful picture of the trust in question is the
result, not just a puff piece.
We provide information, not advice
While we hope that you find the research we publish useful, and
we believe it will help you to make a more informed decision, but
we must of course stress that none of the research published here
constitutes a recommendation, or advice, and you should not think
that - just because we've published a report on a trust - we
believe that trust is a 'buy'. Please read our terms and
conditions.
If you want to manage your own investments we hope that this
website is a useful source of information which helps you to do
that, however if you are in any doubt, you should speak to a
financial adviser.
Pascal Dowling
Kepler Partners
pascal@keplerpartners.com
www.trustintelligence.co.uk
www.keplerpartners.com
International Biotechnol... (LSE:IBT)
Historical Stock Chart
From Apr 2024 to May 2024
International Biotechnol... (LSE:IBT)
Historical Stock Chart
From May 2023 to May 2024